Biogen (BUE:BIIB) EPS without NRI

: ARS3,123.41 (TTM As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

Biogen's earnings per share without non-recurring items for the three months ended in Mar. 2023 was ARS527.46. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2023 was ARS3,123.41.

During the past 12 months, Biogen's average earnings per share (NRI) Growth Rate was 120.50% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -12.70% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 1.10% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Biogen's EPS without NRI or its related term are showing as below:

BUE:BIIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66 Med: 26.65 Max: 205.2
Current: -12.7

During the past 13 years, Biogen's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 205.20% per year. The lowest was -66.00% per year. And the median was 26.65% per year.

BUE:BIIB's 3-Year EPS without NRI Growth Rate is ranked worse than
77.74% of 822 companies
in the Drug Manufacturers industry
Industry Median: 11.15 vs BUE:BIIB: -12.70

Biogen's EPS (Diluted) for the three months ended in Mar. 2023 was ARS527.46. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was ARS3,123.41.

Biogen's EPS (Basic) for the three months ended in Mar. 2023 was ARS531.41. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2023 was ARS3,136.37.

Biogen EPS without NRI Historical Data

The historical data trend for Biogen's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS without NRI

813.67

1,878.09

2,018.22

1,050.30

3,498.86

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
EPS without NRI																221.19	871.19	1,089.37	635.39	527.46

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's EPS without NRI, along with its competitors' market caps and EPS without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen EPS without NRI Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's EPS without NRI distribution charts can be found below:

* The bar in red indicates where Biogen's EPS without NRI falls in comparison to its industry or sector. The grey bar indicates the EPS without NRI's extreme value range as defined by GuruFocus.

Biogen EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS3,123.41

Biogen (BUE:BIIB) EPS without NRI Explanation

A Non Operating Income refers to an entry that appears on a company's financial statements that is unlikely to happen again. It represents a one-time expense involving an unpredictable event and is not part of a firm's normal, day-to-day operations.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Biogen EPS without NRI Related Terms

Thank you for viewing the detailed overview of Biogen's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » EPS without NRI

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.